Skip the development risk. License our ready dossiers and fast-track your path to market authorization.
Indication: Second-line Anti-retroviral medication indicated in combination with other antiretroviral agents, for the treatment of human immunodeficiency virus type 1 (HIV-1) infections.
Development Strategy: Similar to that of the Innovator brand
Dosage Form & Strengths: 100mg & 200mg Tablets
Download Case StudyIndication: Targeted treatment for specific advanced and mutated cancers such as Ovarian and Breast cancers.
Development Strategy: Similar to that of the Innovator brand
Dosage Form & Strengths: 100mg & 150mg Film-coated Tablets
Download Readiness InfoIndication: Treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or newly diagnosed acute myeloid leukemia (AML).
Development Strategy: Similar to that of the Innovator brand
Dosage Form & Strengths: 10mg, 50mg & 100mg Film-coated Tablets
Download Readiness InfoIndication: Treatment of advanced prostate cancer, including both metastatic and non-metastatic castration-resistant or castration-sensitive forms.
Development Strategy: IP-Compliant
Dosage Form & Strengths: 160mg Film-coated Tablets
Download Readiness InfoIndication: Treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC).
Development Strategy: IP-Compliant
Dosage Form & Strengths: 60mg & 240mg Film-coated Tablets
Download Readiness InfoBeyond formulations similar to that of the innovator.
Bypass years of formulation development.
Continue sourcing from us as finished dosage forms (FDFs) or Ready-to-Compress (RTC) Intermediates, or transfer manufacturing locally.
Developed with global agency submissions in mind.
Dossier licensing opportunities allow pharmaceutical companies to license ready-developed generic drug dossiers to accelerate regulatory approval and market entry.
Dossier licensing helps companies avoid development risks and bypass lengthy formulation development processes, enabling faster entry into the market.
We offer fully developed generic drug dossiers, with a specialized focus on oncology, anti-retroviral, high-potent and difficult-to-develop generics.
Pharma partners seeking marketing authorization in their target markets can benefit from these services.
The dossiers are IP-compliant as they go beyond formulations similar to those of the innovator.
Licensing enables faster go-to-market (GTM) by eliminating lengthy development timelines and reducing overall time required to commercialize products.
The dossiers are created by a team with decades of formulation development, scale-up, and manufacturing experience across multiple global markets.
© 2026 STEER Engineering Pvt. Ltd. All Rights Reserved.
Changing the Way we Make and Take Medicines.
